KRAS and BRAF Mutation Screening in Metastatic Colorectal Cancer Costly in Relation to Benefits, National Cancer Institute Study

Published: Nov 29, 2012

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute.

Back to news